Evidence map›Paper›PMID 42120477›Full record

ArticleExperimental & molecular medicine2026

MeCP2 regulates cell-type-specific functions of depressive-like symptoms in the nucleus accumbens.

Jinhee Bae, Sung Hoon Kim, Sun A Jung, Nazarii Frankiv, Hyunjeong Jin, Eun Mi Hwang, Young-Min Kim, Sangjoon Lee, Heh-In Im

Abstract read
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jinhee BaeCenter for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Sung Hoon KimBiomaterials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Sun A JungCenter for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Nazarii FrankivCenter for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Hyunjeong JinCenter for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Eun Mi HwangCenter for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Young-Min KimBiomaterials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Sangjoon LeeCenter for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Heh-In ImCenter for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea. him@kist.re.kr.ORCID http://orcid.org/0000-0002-4763-5009

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methyl-CpG binding protein 2 (MeCP2) is a chromatin-associated transcriptional regulator that modulates neuronal gene programs in response to environmental stimuli. Although MeCP2 has been implicated in stress responses and depression, its cell-type-specific functions within defined limbic circuits remain incompletely understood. Here, using a chronic restraint stress (CRS) model, we show that CRS selectively reduces MeCP2 protein in dopamine D2 receptor (D2R)-expressing medium spiny neurons in the nucleus accumbens (NAc). D2R-restricted MeCP2 knockdown was sufficient to increase immobility in the forced swim test, whereas Cre-dependent restoration of MeCP2 in NAc D2R neurons attenuated CRS-associated behavioral alterations across affective coping, anxiety-like behavior and reward sensitivity. Ex vivo multielectrode array recordings combined with optogenetic stimulation revealed that CRS-associated suppression of NAc activity was normalized toward control levels by MeCP2 restoration. To profile molecular correlates, we performed cell-type-resolved GeoMx digital spatial transcriptomics in virally labeled NAc D2R neurons and found that MeCP2 overexpression was associated with attenuation of CRS-linked transcriptional perturbations, prominently involving synaptic and neuronal communication-related programs. In parallel, we detected CRS-responsive molecular signatures in the ventral pallidum that shifted with NAc D2R-restricted MeCP2 restoration, although these downstream profiles are not projection-resolved. Collectively, our findings identify a D2R neuron-biased role for MeCP2 in the NAc and support the view that restoring MeCP2 in this cell population is associated with mitigation of CRS-induced depression-like phenotypes and accompanying circuit/transcriptomic signatures. Chronic restraint stress (CRS) reduces MeCP2 protein in nucleus accumbens (NAc) D2 receptor (D2R)-expressing neurons, suppressing activity- and synapse-related programs and promoting depressive-like behaviors. Cell-type-specific restoration of MeCP2 in NAc D2R neurons normalizes neuronal activity and attenuates behavioral deficits, accompanied by coordinated transcriptional shifts involving synaptic organization, glutamatergic signaling, potassium channel activity and cytoskeletal regulation. CRS-responsive molecular signatures in the ventral pallidum (VP) show partial normalization in association with MeCP2 upregulation (VP bulk ROIs). Together, these findings implicate MeCP2-dependent regulation of NAc D2R neuron state in stress-related outcomes.

Indexed as

DepressionMethyl-CpG-Binding Protein 2Nucleus AccumbensAnimalsDisease Models, AnimalMaleMedium Spiny NeuronsMiceNeuronsReceptors, Dopamine D2Mecp2 protein, mouseMethyl-CpG-Binding Protein 2Receptors, Dopamine D2

Identifiers

PMID42120477
PMCPMC13234275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.